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Background
Challenges in eliminating malaria
As an increasing number of countries have intensified control 
efforts and are moving towards elimination of malaria, national 
malaria programs face new challenges understanding the nature 
and extent of residual transmission and tailoring their responses 
appropriately. As endemicity declines, transmission has been 
reduced and malaria has become more heterogeneous and is 
often concentrated in specific localities or populations1–3. Part of 
the response to this challenge, outlined in the WHO’s Global 
Technical Strategy4, is strengthening malaria surveillance as a 
core intervention to better monitor and evaluate interventions. 
However, progress in reducing malaria burden globally is stall-
ing in the face of contracting financial resources5, and the need to 
maximize the efficiency of resource targeting and monitor impact 
is therefore increasingly critical. Accurate measurement of trans-
mission can help programs to select and deploy optimal sets of 
interventions to appropriate areas more efficiently and subse-
quently monitor their impact6. Among the more critical questions 
facing programs are: i) How to know when local transmission 
has been interrupted? ii) How to measure spatial variation in 
transmission risk accurately and efficiently in order to optimally 
deploy interventions? iii) How to efficiently monitor change in 
malaria transmission over time, whether due to deployed inter-
ventions or other factors? and iv) What additional strategies to 
deploy against P. vivax, in particular against the dormant liver 
stage (hypnozoite) that is undetectable with current diagnostics, 
but causes recurrent infection and perpetuates transmission?
Several tools and metrics, both parasitological and entomological, 
exist for measuring malaria transmission (reviewed previously7,8). 
In most countries, clinical case reporting systems are the back-
bone of malaria surveillance, and when implemented well can 
provide a good overview of where malaria is observed through-
out the country. While an essential component of any malaria 
program, measurement of clinical cases alone has limitations as 
a surveillance strategy. First, cases are typically reported from 
health facilities, but transmission may be occurring elsewhere. 
Second, clinical case reporting will not include asymptomatic 
infections, (e.g. 9–11), which may be driving transmission in 
certain contexts. Third, important sub-populations that may be 
contributing meaningfully to transmission may not come into 
contact with the formal health system, such as migrant laborers 
and those obtaining care in the private sector. Fourth, in many 
countries, data systems remain of poor quality and reporting 
may be incomplete.
As a result of these limitations, routine case reporting is often 
supplemented by malaria prevalence surveys. However, when 
transmission levels decline, obtaining prevalence data at a useful 
scale requires increasingly and prohibitively larger sample sizes12. 
Other transmission metrics include the entomological inoculation 
rate and vectorial capacity; these are seldom measured beyond 
sentinel sites due to the complexity of implementation, limit-
ing their usefulness for understanding patterns of transmission 
across a region. Novel solutions are thus needed to supplement 
existing tools for measuring transmission patterns across low 
transmission areas7. Availability of flexible tools that can effi-
ciently provide additional information regarding spatial and 
temporal variation in transmission would complement existing 
approaches and activities. Given the timelines for elimination 
that have been established in many countries, the development of 
such tools has become increasingly critical7,13.
Potential advantages of measuring exposure
Measuring recent exposure to malaria is useful for understanding 
transmission risk in low transmission and elimination settings. 
The concept of exposure is different from incidence or preva-
lence in that it measures infection in the recent past (e.g. 6, 12, 
or 24 months) and not only new or ongoing infections. In other 
words, instead of identifying only individuals who are infected 
with Plasmodium blood-stage infections on the day of testing, 
an approach using exposure identifies individuals who have had 
at least one infection during a defined period in the recent past. 
Measuring exposure has advantages over other methods for 
low transmission settings. In these settings, when using diagnos-
tic methods based on detection of circulating parasites, even the 
most sensitive molecular assays will only detect the minority of 
actively infected individuals because many infections will have 
hard-to-detect low parasite densities, or in the case of P. vivax 
liver-stage-only infections, which are simply undetectable. More-
over, even the most sensitive tests will miss individuals who 
have recently cleared infections but may have contributed to 
and thus reflect transmission.
Population surveys over large geographic areas (e.g., an entire 
eliminating country or province) can only test a small fraction 
of the total population over a narrow window of time. This limi-
tation means that determination of geographical areas with 
higher transmission compared to other regions will require large 
sample sizes (often exceeding 5,000-10,000) if parasite preva-
lence is low and only active infections are evaluated. Sample size 
requirements are potentially even larger if high spatial resolu-
tion (e.g., village or sub-district level) is required for efficient 
targeting of interventions8, and similar limitations exist for 
evaluating demographic risk groups. In comparison, a sensitive 
test for recent exposure, by capturing infections that occur over 
a period of time rather than at a single time-point, will require 
a smaller sample size to yield the same information on whether 
transmission has been occurring, and if so to what degree. Alter-
natively, instead of decreasing the size and cost of a survey, by 
measuring recent exposure a survey with a fixed budget and 
sample size can yield greater spatial resolution and thus more 
information about how transmission varies across the region of 
interest than would be possible with conventional diagnostics. 
Another highly pragmatic benefit of measuring exposure instead 
of active infection relates to the timing of surveys. Optimally, 
parasite prevalence surveys are conducted during the malaria 
transmission season, coinciding with heavy workloads for 
programs and challenging conditions during the rains. The 
timing of malaria exposure surveys is more flexible because the 
test captures information over a span of time that is longer than 
the time of the survey, allowing programs to conduct a survey 
after the rainy season, for example.
These efficiencies have the potential to yield more information 
about transmission patterns without requiring more financial 
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and operational investment than is already being made by elimi-
nation programs. Programs have limited financial resources 
and face significant operational constraints (e.g. insufficient 
human resource capacity, transport, and logistics). New 
diagnostic methods that allow sensitive detection of recent 
exposure and that can be easily implemented in low-resource 
settings could play a major role in measuring progress toward 
malaria elimination in these settings and in aiding the design and 
development of interventions.
Antibodies are the best operationally-relevant tool for 
measuring exposure
The total Plasmodium proteome is thought to contain >5,000 
distinct proteins, many hundreds of which have been shown 
to be recognized by the human immune system. Antibodies to 
many of these proteins are efficiently induced and boosted by 
Plasmodium infections and persist in decreasing titers over 
several months to years after the clearance of the blood-stage 
infections14–16, making them potential markers of not only current 
but also recent and historic exposure.
In low-transmission settings or in populations with limited 
prior exposure (e.g. children), antibodies have been shown to 
be strongly linked to exposure17. Antibody responses have also 
been shown to correlate closely with transmission intensity and 
for historically low- and moderate-transmission settings are a 
potentially more efficient transmission measure than infection 
prevalence or incidence rate18,19. Antibodies can be measured 
with relatively simple assays, including inexpensive laboratory-
based assays and point-of-contact tests similar to those devel-
oped for other infectious diseases such as HIV, influenza and 
leishmaniasis20–22. Antibody detection may thus be more sensi-
tive, and potentially lower-cost than nucleic acid detection for 
identifying the ongoing presence of malaria transmission in 
populations. 
The antibody response to each parasite protein has different 
kinetics, i.e. different rates of acquisition, boosting, and decay, 
and researchers have now started to study these antibody kinetic 
profiles for many antibodies to P. falciparum and P. vivax, and 
to characterize their suitability for estimating recent exposure in 
different age groups and transmission settings23. Several ongoing 
efforts are using this information to identify antibody signatures 
that are reliable, quantitative measures of recent exposure to 
malaria parasites24–28. In parallel with biomarker identification, 
antigen production methods, analytics and technology plat-
forms have advanced sufficiently to generate malaria antibody 
assays that will be field deployable in the near future. Detailed 
consideration of assay design and development is beyond 
the scope of this article, but has been recently reviewed29. An 
important advance, is the measurement of multiple antibody 
responses in combination to increase the accuracy of estimates 
of recent exposure for each individual screened. The ability 
to obtain more accurate data on recent exposure from each 
individual by using antibody signatures allows for more accurate 
estimates for populations and for more flexibility in sampling, 
providing a departure from more cumbersome age stratified 
serological approaches used in the past.
Malaria serology convening, Paris, 6–7 June 2017
In light of global malaria elimination targets and recent progress 
in malaria serology research, a meeting was convened in June 
2017 to understand the state-of-the-art in development of 
antibody assays for malaria surveillance (e.g., biomarker identifi-
cation, statistical analysis, diagnostic technology platforms, and 
operational work). A total of 39 representatives from 28 institutions 
participated. Given the scientific and operational advances, it was 
timely to assess the range of applications with a view to prioritiz-
ing them for further investment and development. As such, a key 
aim of the meeting was to review potential use-case scenarios, 
including experiences using and evaluating serological biomarkers 
in control and elimination programs. This paper synthesizes 
and builds upon the discussions of use-case scenarios with an 
aim towards focusing research and investment on those applica-
tions that will have the greatest impact on malaria transmission 
reduction and elimination. The use cases described herein are 
purposely technology platform-neutral, do not refer to specific 
detection targets, and, with one exception, are relevant to both 
P. falciparum and P. vivax. It should also be noted that whilst all 
use cases refer to measurement of recent exposure using antibod-
ies, the period of time over which past exposure will be informa-
tive may vary by use case and epidemiologic setting as well as 
the biological and technical constraints of the assay. As such, in 
depth consideration of the specific period of time for recency is 
beyond the scope of this review and not specified below, but in 
general was agreed to be in the range of six months to three 
years.
Use cases for serological markers of exposure
Spectrum of applications
Many uses of malaria antibody assays have been described 
previously (reviewed in 30–32). These vary greatly in their 
purpose; while some are purely surveillance tools for character-
izing transmission, others are used to trigger a control approach 
or measure the effect of an intervention. These uses also differ 
in how they are applied – at the individual or population level – as 
well as where on the transmission spectrum they are most relevant. 
Recently, additional approaches have been proposed, including 
the use of malaria antibody assays to target interventions to 
specific populations, and at least for P. vivax, to individuals.
To date, the various potential use-case scenarios have neither 
been accurately described nor prioritized. A detailed understand-
ing of which functions the test is expected to perform and on 
what target population is a pre-requisite for the development 
of detailed target product profiles, and consequently for further 
investment and actual product development. In the diagnostics 
industry, these decisions are typically made based on market 
research and profitability analysis, but for a global health 
market of limited size, investment decisions in new product 
development should be informed by the health impact associated 
with specific use cases in addition to market considerations. If a 
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sufficiently robust case can be made, the funding mechanisms 
that drive malaria diagnostics markets (predominantly bilateral 
and multilateral aid agencies) provide a conducive environment 
for providing needed support.
As such, we consider the use-case scenarios for malaria anti-
body assays through two lenses. Firstly, does testing for exposure 
offer compelling advantages, or additional value, over more 
routinely used metrics? Secondly, does the application provide 
critical information to control and elimination programs? Using 
these filters, the following five use-case scenarios are reviewed: 
i) documenting the absence of transmission over a given geo-
graphic space; ii) stratification of transmission level; iii) meas-
uring the impact of interventions and monitoring changes in 
malaria transmission; iv) decentralized immediate response; and 
v) serological testing and treatment for P. vivax hypnozoites 
(Figure 1). 
Whilst discussions focused primarily on low transmission, 
pre- and peri-eliminations settings, whether exposure testing 
in general and some of these same use cases in particular may 
also have utility in higher transmission settings (e.g. measuring 
changes in transmission that follow interventions but are not 
detectable by parasite prevalence measurements8, understanding 
population immunity to help identify populations at high risk32) 
was also discussed.
Priority use-case scenarios of serological markers of 
exposure
Use Case 1: Document absence of transmission. One end of 
the transmission spectrum is the absence of transmission in a 
defined area (Table 1). Malaria antibody tests with appropriate 
performance characteristics would provide a sensitive tool for 
quickly confirming the absence of transmission via the absence of 
antibodies specific for recent malaria exposure30,32. For example, 
a program may have no passively detected indigenous cases in 
an area and want evidence from another reliable approach about 
the absence of transmission before scaling back an intervention 
(e.g. IRS) or shifting focus to prevention of reintroduction. 
In this use-case scenario, antibody testing would be used to 
document the absence of transmission over a defined period 
of time, at the subnational or district level, along with routine 
passive case detection and case investigation (which are required 
for WHO certification of elimination) and metrics like annual 
blood slide examination rates. As with all of the other population- 
based use cases described below (Use Cases 2-4), screening may 
occur through surveillance of the general population or within 
relevant sentinel populations chosen because they are at high-
est risk or are more efficient to screen (e.g. migrants/mobile 
populations, pregnant women, school children). Depending on 
the population screened, antibody-detection testing may occur 
in participants captured by active screening (e.g., cross-sectional 
surveys) or passively through sentinel populations (e.g., screen-
ing at health facilities or prenatal clinics). This use case does not 
necessarily require a point-of-contact test, since these pro-
grammatic surveys can be evaluated by a central laboratory. A 
point-of-contact format may also be considered, in particular if 
confirmation of ongoing transmission is linked to an immediate, 
decentralized programmatic response (see Use Case 4 below). 
Use Case 1 will require an antibody marker with high spe-
cificity for recent exposure, and, depending on the elimination 
related goals, species specificity33. Some antibodies can persist 
for extended periods in some individuals34, which may lead to 
false positives. Therefore, careful selection of antibodies with 
relatively short half-lives but consistent boosting in those exposed 
will be required. Combining antigens with different kinetic 
profiles in the same test may be possible (either via multiplex 
assays or separate targets on point-of-contact tests) which could 
improve the accuracy of time-since-exposure estimates. Similarly, 
targeting of testing to known high-risk groups may further the 
effectiveness of this approach.
Use Case 2: Stratification of transmission. As malaria ende-
micity drops to low or very low levels, transmission becomes 
Figure 1. Priority applications of serological markers of exposure.
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increasingly heterogeneous, with pockets of residual transmission 
surrounded by large areas with little or no local transmission1. 
In these settings, blanket coverage of interventions may not be 
cost-effective, and surveillance for stratification becomes an 
integral part of control and elimination programs4,35. In order 
to target interventions effectively, national programs need to 
stratify the country and populations into different transmission 
levels and to use this information to guide interventions.
In areas where transmission is highly focalized and routine 
surveillance coverage potentially incomplete, antibody data can 
augment clinical case data to provide a more granular picture of 
recent transmission (e.g. to direct locally targeted interventions). 
This may be especially true if the incidence of asymptomatic 
infections is high, as these infections would be missed by case 
reporting systems. In this use-case scenario, seroprevalence data 
could be added to geo-spatial mapping programs (e.g. the Malaria 
Atlas Project), facilitating use of these data for programmatic 
stratification and action. For this use case a lab-based or point- 
of-contact test are both possible. Centralized testing may appeal 
because stratification usually occurs over higher administrative 
levels and would likely coincide with annual program activi-
ties. Stratification will require antibody markers with optimal 
balance between sensitivity and specificity for recent exposure 
across a range of transmission levels (e.g. from no to moderate 
transmission), as well as corresponding guidance on sampling. 
This will enable targeting of resource intensive interventions 
to areas of highest transmission or areas highly susceptible to 
interruption of transmission, while enabling a scale-back or 
redirection in other areas.
Use Case 3: Measure impact of interventions. Ideally, programs 
would have the capacity to routinely measure the impact of 
interventions to ensure their continued effectiveness. However, 
existing surveillance systems often do not provide sufficient 
information on effectiveness despite the millions of dollars spent 
on malaria control interventions every year.
For impact evaluation purposes, antibody markers of exposure 
can be an effective measure. In practice, antibody testing would 
likely be used in two settings: 1) when new interventions are being 
piloted or implemented for the first time; and 2) intermittently 
thereafter to monitor the real-world effectiveness of these measures, 
especially when there is reason to suspect potential compromise 
of effectiveness.
The Garki project is a classic example of the utility of using 
antibodies to evaluate changes in transmission intensity after 
initiation of interventions36. More recently, studies are begin-
ning to use antibodies more specific for recent exposure, i.e. 
that have shorter serum half-lives. For example, operational 
research on focal mass drug administration (MDA) and vector 
control in Namibia is using antibody data that capture recent expo-
sure as a study outcome37. Serological test characteristics for this 
use case are similar to those required for the risk stratification 
use case above.
Use Case 4: Decentralized immediate response. In this use 
case, malaria teams would use point of contact antibody tests to 
survey a small proportion of the population, and results would 
inform an immediate action at the focal level (village, house-
hold, defined high risk populations, etc.). As serological positivity 
is expected to exceed infection prevalence, antibody testing 
would generate more granular data on which to base decisions. 
Operationally, the response to positive antibody results could 
vary (e.g. focal larval control, IRS, focal testing and treatment 
or focal MDA, education, etc.) and would be triggered by a 
predefined threshold of positivity in the sampled population. The 
requirement for decentralized decision-making and real-time 
data to inform immediate response distinguishes the current use 
case from those discussed earlier in that it requires a point-of- 
contact test.
While such interventions could be conducted with parasite 
antigen-detecting rapid diagnostic tests (RDTs), especially 
highly sensitive RDTs, a point-of-contact antibody detection 
tests could have a higher sensitivity in detecting recent events 
and thus potentially require a smaller sample size and/or be used 
on different target populations, i.e. known high-risk groups such 
as forest workers in certain South East Asian settings who may 
harbor hypnozoites. Similar types of interventions have also 
been attempted with molecular methods38,39; however, these are 
typically cumbersome and costly to implement in the field, 
and turnaround time, even with mobile laboratory set-ups, is 
not as fast as with point-of-contact tests. In the case of P. vivax, 
serological markers may be able to identify hypnozoite carriers 
(see Use Case 5). While we are not aware of this type of inter-
vention being currently deployed in malaria using antibody 
tests, similar approaches have been tried with RDTs40 and 
molecular methods39 with mixed results, and are routinely imple-
mented with antibody testing in other neglected tropical diseases 
(for example the transmission assessment surveys for filariasis41).
Use Case 5: P. vivax sero-test-and-treat. Currently, there are no 
tests to assess whether an individual is infected with hypnozoites, 
the dormant, liver-stage forms of P. vivax (and P. ovale) that 
cause relapses and are asymptomatic42. Hypnozoites, which can 
re-activate months or even 1-3 years after clearance of the pri-
mary blood-stage infection43, account for up to 80% of all P. vivax 
infections and are thought to contribute substantially to trans-
mission44. Hypnozoites require radical cure with primaquine or 
tafenoquine to avoid recurrent infections, which potentially result 
in symptomatic disease and transmission to mosquitoes. By defi-
nition, dormant stages are not detected by blood-stage infection 
tests, thus, with current tools programs are faced with a choice 
between missing carriers with mass test and treatment (MTAT) 
or treating whole populations with MDA45. The ability to safely 
perform MDA is limited in part due to the risk of 8-aminoquino-
line-induced haemolysis in glucose-6-phosphate dehydrogenase 
(G6PD)-deficient people46. This is of particular concern in low 
endemicity settings where up to 85–95% of people treated do 
not require treatment, as they do not have hypnozoites, but for 
safety reasons need to be tested for G6PD deficiency prior to 
receiving 8-aminoquinolines and monitored for compliance, a 
challenging and resource-intensive undertaking. An alternative 
parasite clearance intervention is MTAT, but without a sensi-
tive assay that identifies people carrying only hypnozoites this 
approach is likely to be ineffective47 because it would miss a large 
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proportion of the reservoir48. As all P. vivax strains—except for the 
hibernans strains currently thought to be restricted to the Korean 
peninsula—cause primary blood-stage infections followed by 
a primary relapse within 1 – 9 months43, serological markers 
able to detect a P. vivax (blood-stage) infection in around the 
previous 9 months could act as an effective proxy for potential 
hypnozoite carriage. 
In this scenario, a population is screened and those individuals 
testing positive for recent P. vivax exposure with a point-of- 
contact test would receive radical cure (unless contraindicated or 
recent treatment can be confirmed). This strategy is denoted sero-
logical testing and treatment (SeroTAT). While not all antibody-
positive individuals will harbor hypnozoites, serological screening 
will avoid most of the large-scale overtreatment associated with 
MDA, and therefore help programs implement parasite treatment 
interventions that lead to clearance of hypnozoites. Program-
matic implementation is likely to require a test that can detect 
recent exposure to P. vivax with high sensitivity (to assure 
efficacy) and good specificity to avoid over-treatment. While this 
intervention has yet to be fully evaluated, transmission decline and 
eventual elimination of malaria in some Southern Brazil locali-
ties in the 1980s was attributed at least in part to treatment guided 
by malaria serology49. Serological testing was also used to target 
focal MDA programmes for the elimination of P. vivax in 
Jiangsu province, China from 2000–200945. Serological test 
and treat approaches may also be an appropriate intervention to 
eliminate residual pockets of P. ovale transmission and could be 
useful for the screening of returning travelers or migrants that 
move from a P. vivax endemic area to a no longer endemic (but 
receptive) area. 
Toward implementation of antibody-detecting surveillance 
and response
Currently, malaria antibody tests have primarily been used in the 
research context, and a number of steps are required if malaria 
programs are to integrate antibody testing more broadly into 
surveillance and response. Among these steps are proof-of- 
concept studies on the impact of interventions involving the 
use of malaria antibody tests (e.g. decentralized immediate 
response, SeroTAT), and development of operational strategies for 
transmission monitoring use cases (e.g. sampling strategies). 
Simultaneously, researchers continue to refine biomarkers and 
analytical methods, while developers have begun work to migrate 
these assays to appropriate technology platforms. Importantly, 
quality assurance (including the establishment of appropriate 
standards) should be considered comprehensively at this stage 
in order to ensure that results are reliable and comparable50. 
In addition to malaria antibody tests that provide sufficiently 
reliable answers to the key questions faced by programs, it is 
important that any new tools address the context and conditions 
of use. Elimination programs have limited finances and face 
significant operational constraints, such as the scarcity of trained 
staff and transportation bottlenecks, especially at subnational 
levels. With the exception of P. vivax SeroTAT (Use Case 5), 
there are existing transmission metrics that might perform the 
same role as malaria antibody testing, and it is important that any 
new test is considered in this context. When used in surveillance, 
monitoring, or stratification (Use Cases 1–3), antibody testing will 
most likely be used in conjunction with other tools, and there-
fore programs must critically consider the value added in order 
to justify the investment of limited time and resources. Additional 
investment required will vary considerably depending on how 
tests are integrated into surveillance activities. In some cases, 
the addition of these tools will add minimal cost and effort, 
e.g. antibody testing of dried blood spots already being collected 
as part of a cross-sectional survey or in the context of already 
existing sampling schemes (e.g. antenatal clinic visits). In other 
cases, such as point-of-contact testing for decentralized imme-
diate response, the unit cost per test may be higher; however, 
these may be offset by other savings and operational advantages. 
The potential utility and applications of antibody testing are 
likely to vary by regions and populations, influenced by a range 
of factors such as transmission epidemiology, local resources 
and infrastructure, population size and mobility, and access. In 
some settings serology will be a valuable addition, in others it 
may be less useful.
Across all applications, expected situations of use will include 
resource poor settings, where environmental conditions for both 
specimen storage and performing assays may not be well con-
trolled. The tests or sample collection systems must therefore be 
robust enough to withstand extreme conditions. Because sam-
ple collection, and in many cases testing itself, is likely to be 
performed by field workers with little training, ease-of-use is 
paramount. These requirements will likely be easier to achieve 
for Use Cases 1–3, which do not require a point-of-contact test-
ing (e.g. using dried blood spot samples) than for Use Cases 
4 and 5, which require a field stable point-of-contact test. The 
use of a point-of-contact test and remote data collection may be 
an advantage in remote locations, or in areas among populations 
with difficult or infrequent access (e.g. geographically remote 
settings, conflict and disaster settings, mobile populations), but 
is only essential if positive test results are followed by an imme-
diate programmatic response (either individual treatment or 
implementation of population-based interventions, i.e. Use Cases 
4 and 5). The test result must also be unambiguous, providing 
actionable data to the relevant end-user, be it a field worker 
reading a binary a point-of-contact test, or a district manager 
receiving a report from the laboratory. While the turn-around-
time for antibody tests triggering immediate interventions must 
be as rapid as possible, an important consideration for other use 
cases may be simplifying batch processing for laboratory-based 
methods to make these tests more accessible to programs with 
limited resources while still providing data within the appropriate 
timeframe needed for decision-making. 
Finally, it will be important to engage global and national malaria 
programs, affected communities, non-governmental organisa-
tions, donor agencies and malaria research institutes on the 
concept of measuring exposure and various use case scenarios 
for malaria antibody tests. Their feedback is important to further 
prioritization and target product profile development; however, 
since antibody-detection testing is a departure from the traditional 
focus on direct parasite detection, a thoughtful and proactive 
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engagement strategy is needed. Modeling of likely cost-benefits 
of resource targeting and acceleration of elimination will be an 
important aspect of this, along with building a track record and 
evidence base through demonstration studies.
As discussed, the driving rationale for antibody testing is its 
pragmatic, practical advantages, for example facilitating more 
nimble surveillance by reducing sample sizes required for pre-
cise, actionable data; the ability to have a rapidly deployable 
test that provides timely intelligence in the field to target local 
interventions; and its unique potential to identify hypnozoite 
carriers. Given the contextual challenges that malaria programs 
face, and the range of malaria typologies that exist today, anti-
body testing is likely to have a meaningful impact on malaria 
elimination efforts on multiple fronts. Current technological 
advances suggest the potential for development of operational, 
standardized antibody-detecting tools for malaria surveillance and 
response in the short term. Validation of at least one such 
approach would likely pave the way for a set of antibody-detection 
assays to address the five use cases outlined here. 
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